Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.60
-0.2%
$0.57
$0.16
$0.82
$639.84M0.252.88 million shs1.51 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$46.37
-3.1%
$42.55
$31.42
$58.26
$3.13B1.27385,050 shs244,062 shs
Metsera Inc. stock logo
MTSR
Metsera
$29.45
+2.0%
$27.47
$12.30
$37.99
$3.09BN/A1.07 million shs589,745 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$28.16
+1.6%
$27.42
$18.92
$81.73
$3.17B0.624.04 million shs2.38 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00%-15.78%+7.60%+87.33%+224.61%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%-2.43%-5.05%+24.60%+9.87%
Metsera Inc. stock logo
MTSR
Metsera
0.00%+3.01%+2.72%+75.30%+2,944,999,900.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+6.18%+4.14%+24.49%-44.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.5677 of 5 stars
0.03.00.00.02.90.80.0
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1.9914 of 5 stars
3.51.00.00.02.12.50.0
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3571 of 5 stars
4.51.00.04.71.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3.00
Buy$74.5060.68% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0086.76% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15209.50% Upside

Current Analyst Ratings Breakdown

Latest ELTP, MLTX, MTSR, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/3/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$67.00
5/19/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$61.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$78.00 ➝ $80.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/30/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.61$0.02 per share34.91$0.05 per share11.98
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$7.09 per shareN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$20.11MN/A0.00N/A-25.70%-6.92%-3.94%8/14/2025 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest ELTP, MLTX, MTSR, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/12/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.76-$0.63+$0.13-$0.63N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.12
3.27
1.90
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.18
21.11
21.11
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
12.02%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.01 million56.32 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

VKTX - Viking Therapeutics Inc Sustainability - Morningstar
Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...
VKTX Viking Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.60 0.00 (-0.15%)
As of 07/3/2025 12:59 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$46.36 -1.50 (-3.12%)
As of 07/3/2025 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera stock logo

Metsera NASDAQ:MTSR

$29.45 +0.59 (+2.04%)
As of 07/3/2025 01:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$28.16 +0.44 (+1.59%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$28.04 -0.12 (-0.43%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.